Core Viewpoint - The article highlights the successful launch of the TANK MAX super microwave platform by Shanghai New Instrument, showcasing its innovative capabilities in sample pretreatment for food element detection, emphasizing efficiency and safety in laboratory processes [1][4]. Group 1: Event Overview - The event attracted nearly 20,000 online participants, featuring technical sharing, live demonstrations, and interactive Q&A sessions led by product manager Chen Shuo [1]. - The theme of the event was "Speeding Up Detection by Doubling Efficiency and Halving Time," focusing on the advancements in microwave technology for food safety testing [1]. Group 2: New Standards in Food Element Detection - Professor Liu Guihua from Shenzhen Center for Disease Control provided insights into the revised GB5009.268-2025 standard for multi-element testing in food, discussing the background and key changes [2][3]. - Key topics included the preparation of standard solutions, sample digestion processes, and the importance of unified calculation formulas and detection limits [3]. Group 3: TANK MAX Super Microwave Features - Chen Shuo detailed the technical challenges in food heavy metal detection and how TANK MAX addresses these issues with enhanced digestion capabilities, pressure tolerance, and rapid cooling features [6][7]. - The TANK MAX operates at a maximum temperature of 300°C and a pressure of 20MPa, making it suitable for digesting difficult samples [7][12]. - The device supports simultaneous processing of various sample types, making it versatile for applications in food, pharmaceuticals, environment, and new materials [7][14]. Group 4: Practical Demonstration and Efficiency - During the live demonstration, TANK MAX was used to digest complex samples like tea leaves and vegetable oils, showcasing its user-friendly operation and time-saving features [10][11]. - The system allows for a fully automated digestion process, significantly reducing manual intervention and potential errors [10][11]. - Each sample requires only 2mL of acid, streamlining the digestion process and enhancing overall efficiency [11]. Group 5: Safety and Versatility - TANK MAX includes a corrosion-resistant design capable of withstanding various aggressive reagents, ensuring safety across diverse experimental conditions [13][14]. - The device incorporates multiple safety mechanisms to protect users during the digestion process, enhancing its reliability in laboratory settings [14]. - Beyond food testing, TANK MAX is effective in environmental and chemical analyses, demonstrating its broad applicability [14].

Core Viewpoint - The demand for mineral resources in China is continuously growing, supported by national policies and strategies, leading to a vibrant industry development. Geological and mineral analysis technologies are advancing towards green and intelligent solutions, addressing the increasing complexity of sample analysis and raising the requirements for the sensitivity, stability, and reliability of analytical instruments [2]. Group 1: Industry Development - The industry is experiencing significant technological breakthroughs in elemental analysis techniques represented by ICP-MS, ICP-OES, atomic absorption spectroscopy, and XRF, as well as phase analysis technologies like microscopy and XRD. These advancements are driving technological upgrades and constructing an eco-friendly, efficient modern exploration system to ensure national energy resource security [2]. Group 2: Upcoming Event - The "7th Geological and Mineral Analysis New Technologies and Applications" online seminar will be held on August 14, 2025, organized by the Instrument Information Network. This event aims to explore the latest advancements and innovative applications in the field of analysis technology [4][6]. Group 3: Conference Agenda - The conference will feature various sessions, including: - Field analysis testing technology development and application [5] - High-precision isotope analysis methods based on efficient sampling technology [5] - Applications of Steel Research and Testing equipment in geological mineral elemental analysis [5] - Biological prospecting methods in large lithium resource base evaluation [5] - Applications of high-resolution ICP-OES in the rare earth sector [5] - Analysis testing technology research for high-purity mineral materials [5] - Composition analysis technology for rare earth products and magnetic materials [5] - Solutions for geological mining industry using XRF equipment [5] - Current status of practical rare earth metallurgy analysis technology and standards [5] - Applications of chemical high-resolution ICP-MS in high-purity rare earth testing [5] - Advances in oil and gas geological sample analysis testing technology [5] - Research progress and key technologies in global gold ore standard materials [5]

Core Insights - Gordon Sanghera has announced his resignation as CEO of Oxford Nanopore Technologies (ONT) after 21 years, prompting the board to initiate a search for a successor to lead the company into a new phase of growth and commercialization [1][2][4] - Under Sanghera's leadership, ONT pioneered nanopore sensing technology for sequencing, launching the MinION device in 2015, which has significantly impacted molecular analysis and served over 125 countries [3][4] - The company has faced legal challenges, including a recent lawsuit against BGI Group for patent infringement, which was later withdrawn, indicating potential shifts in the company's market strategy and leadership direction [4] Company Overview - ONT was co-founded by Gordon Sanghera, Hagan Bayley, and IP Group in 2005, with Sanghera serving as CEO since its inception [2] - The company has produced over 14,000 peer-reviewed publications, establishing itself as one of the fastest-growing sequencing companies in recent years [3] Leadership Transition - The board's search for a new leader is seen as a critical step for ONT to continue its success and adapt to industry changes [4] - Sanghera expressed confidence in the company's foundation for ongoing success, suggesting that the timing is right for a leadership change [4]

Core Viewpoint - Revvity reported a revenue of $720 million for Q2 2025, reflecting a 4% year-over-year growth, with life sciences and diagnostics contributing $366 million and $354 million respectively [1][2]. Financial Performance - The revenue for Q2 2025 was $720 million, compared to $692 million in the same period last year, marking a 4% increase [2]. - The GAAP operating income from continuing operations was $91 million, up from $86 million year-over-year, with an operating margin of 12.6% compared to 12.4% in the previous year [2][5]. - Life sciences revenue grew by 5% to $366 million from $349 million, while diagnostics revenue increased by 3% to $354 million from $343 million [2][6]. Future Outlook - Revvity raised its full-year revenue guidance for 2025 to between $2.84 billion and $2.88 billion, anticipating an organic growth rate of 2% to 4% [1][6]. - The adjusted earnings per share forecast was also increased to between $4.85 and $4.95 [6].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 关于开展 2025年北 京市首台（套） 重大技术装备保险费补贴项目申报的通知 各有关单位： 为推动北京市首台（套）重大技术装备示范应用，按照《中关村国家自主创新示范区提升企业创新能力支持资金管理办 法》（京科发〔2024〕13号），现组织开展北京市首台（套）重大技术装备保险费补贴项目受理工作。有关事项通知 如下： 支持内容 对北京市首台（套）重大技术装备给予保险费补贴支持，推动市场应用。 采取后补助方式，对已投保或续保的企业按照相关险种保险费80%的比例给予保费补贴，每家企业每年支持金额不超 过200万元。 支持对象 北京市首台（套）重大技术装备的研制单位。 支持条件 （一）投保首台（套）装备应为有效期内北京市首台（套）重大技术装备。 （二）支持险种包括：质量保证保险、产品责任险、设备运输保险、安装工程一切险及第三者责任险、设计责任险、财 产一切险、机器损坏险、产品保证险、财务损失险、产品召回险、首台（套）重大技术装备综合险。 （三）投保时间须为2024年8月1日（含）到2025年7月31日（ ...

导读： Nature作者 波士顿大学 Ji-Xin Cheng教授、东京大学 Yasuyuki Ozeki教授 莅临，揭秘相干拉曼技术的前世今生。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近 日 ， 哥 伦 比 亚 大 学 Wei Min 教 授 团 队 联 合 波 士 顿 大 学 J i-Xin Cheng 教 授 和 东 京 大 学 Yasuyuk i Ozek i 教 授 ， 在 顶 刊 Nature Photonics发 表 题为 Theor y , innovations and appl ications of s timulated Raman scattering microscopy 的综述，系统揭秘了 相干拉曼——这项被称为光学成像 "超级显微镜" 的技术，凭借 "看分子振动、无标记成像、超高速分辨" 三大核心优势，正彻底改变生物医 学、材料科学和环境监测的研究范式。 为探讨拉曼等技术的前沿突破与应用未来， 第二届化学成像前沿科技及应用高端论坛 将于2025年8月14日至16日在苏州盛大召开， 仪 器 信 息网将 ...

Core Viewpoint - Hefei Gravitational Wave Zhipu Technology Co., Ltd. completed its angel round financing in August 2025, aiming to break foreign technology monopolies and promote domestic substitution in high-end mass spectrometry instruments [2][3]. Group 1: Company Overview - The company focuses on the research, production, and sales of high-end mass spectrometry instruments and has achieved significant technological advancements, particularly in key areas such as ion sources and quadrupole mass analyzers [3]. - Gravitational Wave Zhipu has successfully developed and delivered China's first ion trap quantum computer, showcasing its strong innovation capabilities [3]. Group 2: Financing and Investment - The recent financing round was led by Qiyu Investment and Wofu Venture Capital, with funds primarily allocated for the R&D and production of high-end mass spectrometry instruments [2]. - The company is actively applying for multiple national technology patents and developing several mass spectrometry instruments with independent intellectual property rights [3]. Group 3: Market Validation - Within less than a year of establishment, the company's mass spectrometry products have received initial market validation, evidenced by winning a procurement project for the MS8000 Plus model at Central South University [3]. - The MS8000 Plus model was successfully selected for a procurement project, priced at 2,388,000 yuan, indicating strong demand for high-end research equipment [4].

Core Viewpoint - The company Zhongji Testing (stock code: 872726) has been forced to suspend trading due to insufficient market makers, but its business operations remain unaffected. It is recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, focusing on the research and manufacturing of testing equipment to promote domestic substitution [2][3]. Group 1: Forced Suspension Overview - The forced suspension is categorized as a result of having fewer than two market makers, which is a requirement for trading [5]. - The specific reason for the suspension is the withdrawal of one market maker, leaving only one remaining, which does not meet the minimum requirement [5]. - The suspension took effect on August 8, 2025, and the company will issue announcements every five trading days during the suspension period [3][6]. Group 2: Future Arrangements - The company aims to restore the number of market makers to two or more within 30 trading days; otherwise, the trading method will change to collective bidding [3][7]. - The suspension impacts investor trading and liquidity management, but the company emphasizes that its business operations are not disrupted [3].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 丹娜 （ 天津 ） 生物科技股份有限公司 （ 简称 ： 丹娜生物 ） 的北交所IPO申请于2025年5月9日提交注册 ， 至 今已过三个月仍未注册生效 。 自丹娜生物北交所IPO受理以来经受了诸多质疑 ， 从核心原材料的稳定性风险 、 销售模式合规性 、 募资合理性 、 股份代持问题等多个维度 ， 警示丹娜生物的IPO注册不应操之过急 。 1 、 被指核心产品依赖保护动物 ， 原料供应存危机 丹娜生物主营体外诊断试剂业务 ， 其核心产品酶动力学系列 ， 以鲎血细胞作为原材料 。2021年2月 ， 鲎被列为 国家二级保护动物 ， 导致国内鲎血细胞开采渠道受限 ， 也引发了丹娜生物供应链风险 。 2 、 被指 " 不差钱仍募资 " ， 产能利用不足仍扩产 今年5月的分析文章 ： 一是质疑丹娜生物巨额理财资金与小额募资需求的反差 。 二是质疑其资产负债率极低 （ 2024年末为10.17% ） ， 却选择通过IPO募资建设总部基地 ， 疑似打着研发中心的名义建办公楼 。 3 、 " 捆绑销售 " 的 ...

Core Viewpoint - The company reports a 10% year-over-year revenue growth driven by HiFi sequencing technology, with strong international growth in APAC (+53%) and EMEA (+35%) regions, maintaining full-year revenue guidance of $155 million to $165 million, representing a midpoint growth of 1-7% [2] Financial Performance Analysis - Q2 revenue reached $39.8 million, reflecting a 7% quarter-over-quarter and 10% year-over-year increase [3] - Revenue breakdown: Instrument revenue at $14.2 million (down 4% YoY), Consumables at $18.9 million (up 11% YoY), and Service revenue at $6.7 million (up 57% YoY) [3] - Non-GAAP gross margin improved to 38.3%, exceeding expectations due to higher consumables profit margins [3] - Cash balance stands at $315 million, above expectations, with projected annual cash burn of $115 million, an improvement of $72 million YoY [3] Key Drivers - Revenue growth is primarily driven by international expansion (combined APAC/EMEA growth of 45%) and new customers for the Vega system (60% from new clients) [4] - Ongoing uncertainty in U.S. academic funding continues to suppress instrument demand, while consumables show resilience [4] - Cost optimization measures led to an 18% year-over-year reduction in operating expenses [4] Business Operations - The Revio system has a cumulative deployment of 297 units (15 new units in Q2), with 60% targeting new customers and one-third entering clinical laboratories [5] - The Vega system has a cumulative deployment of 73 units (38 new units in Q2), with 70% used for non-whole genome applications (e.g., microbiome sequencing) [5] - Consumables account for 15% of clinical revenue, with clients like Quest entering commercialization [5] Technological Innovation - The Spark chemical reagent has improved throughput by 33% and reduced sequencing costs, now covering 90% of operations [6] - Multi-purpose intelligent cells (in development) are expected to lower customer costs and enhance company gross margins [6] Market Expansion - Strong international growth includes rare disease research in Nordic hospitals and population sequencing projects in Southeast Asia [8] - Collaborative cases include Haorai Gene in China promoting transfusion medicine applications and Target ALS for global genomic research [8] Future Outlook and Planning - Short-term goals for 2025 include maintaining revenue guidance of $155 million to $165 million, with double-digit growth in consumables offsetting instrument declines [9] - Targeting non-GAAP gross margin improvement to 37-40% (with expectations to exceed 40% by year-end) and controlling operating expenses between $235 million and $240 million [9] Mid to Long-term Strategy - Aiming for positive cash flow by 2027 [10] - Plans to expand clinical and population genomics markets through HiFi technology and multi-omics solutions [10] CEO Insights - The CEO emphasizes the unique advantages of HiFi technology (long reads and simultaneous epigenetic detection) and aims to lower adoption barriers through innovation [11] - Reiterates financial discipline and focuses on clinical translation and scale effects, with a goal to become a leader in genomic medicine [11]